Related references
Note: Only part of the references are listed.Levothyroxine Interactions with Food and Dietary Supplements-A Systematic Review
Agnieszka Wiesner et al.
PHARMACEUTICALS (2021)
Phase II/III, randomized, double-blind, parallel-group study of monthly delayed-release versus daily immediate-release risedronate tablets in Japanese patients with involutional osteoporosis
Satoshi Soen et al.
JOURNAL OF BONE AND MINERAL METABOLISM (2020)
Calcium and/or Vitamin D Supplementation for the Prevention of Fragility Fractures: Who Needs It?
Ian R. Reid et al.
NUTRIENTS (2020)
Interventions to improve adherence to anti-osteoporosis medications: an updated systematic review
D. Cornelissen et al.
OSTEOPOROSIS INTERNATIONAL (2020)
Food Effects on Oral Drug Absorption: Application of Physiologically-Based Pharmacokinetic Modeling as a Predictive Tool
Lisa Cheng et al.
PHARMACEUTICS (2020)
Food-Drug Interactions Among the Elderly: Risk Assessment and Recommendations for Patients
Pawel Pasko
ENCYCLOPEDIA OF BIOMEDICAL GERONTOLOGY, VOL 2 (2020)
Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Clinical Practice Guideline
Richard Eastell et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2019)
Adherence to bisphosphonates in the general population: a study in patients referred to a primary care service
Pietro Donato et al.
ARCHIVES OF OSTEOPOROSIS (2019)
A systematic review of factors affecting medication adherence among patients with osteoporosis
C. T. Yeam et al.
OSTEOPOROSIS INTERNATIONAL (2018)
The role of calcium supplementation in healthy musculoskeletal ageing
N. C. Harvey et al.
OSTEOPOROSIS INTERNATIONAL (2017)
Pharmacokinetics, Dose Proportionality, and Bioavailability of Bazedoxifene in Healthy Postmenopausal Women
William McKeand
CLINICAL THERAPEUTICS (2017)
Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women: A Clinical Practice Guideline Update From the American College of Physicians
Amir Qaseem et al.
ANNALS OF INTERNAL MEDICINE (2017)
Interaction between Bisphosphonates and Mineral Water: Study of Oral Risedronate Absorption in Rats
Akihisa Itoh et al.
BIOLOGICAL & PHARMACEUTICAL BULLETIN (2016)
Bisphosphonates: Pharmacokinetics, bioavailability, mechanisms of action, clinical applications in children, and effects on tooth development
Ana Prates Soares et al.
ENVIRONMENTAL TOXICOLOGY AND PHARMACOLOGY (2016)
Pharmacokinetics and Tolerability of Minodronic Acid Tablets in Healthy Chinese Subjects and Food and Age Effects on the Pharmacokinetics
Ying Zhou et al.
CLINICAL THERAPEUTICS (2015)
Treatment of postmenopausal osteoporosis with delayed-release risedronate 35 mg weekly for 2 years
M. R. McClung et al.
OSTEOPOROSIS INTERNATIONAL (2013)
Alendronate sodium hydrate (oral jelly) for the treatment of osteoporosis: review of a novel, easy to swallow formulation
Kazuhiro Imai
CLINICAL INTERVENTIONS IN AGING (2013)
Eliminating the need for fasting with oral administration of bisphosphonates
Michael Pazianas et al.
THERAPEUTICS AND CLINICAL RISK MANAGEMENT (2013)
Efficacy and safety of a novel delayed-release risedronate 35 mg once-a-week tablet
M. R. McClung et al.
OSTEOPOROSIS INTERNATIONAL (2012)
Clinical utility of risedronate in postmenopausal osteoporosis: patient considerations with delayed-release formulation
Plamen Kinov et al.
INTERNATIONAL JOURNAL OF WOMENS HEALTH (2012)
Bioadhesive Microspheres for Bioavailability Enhancement of Raloxifene Hydrochloride: Formulation and Pharmacokinetic Evaluation
Ram K. Jha et al.
AAPS PHARMSCITECH (2011)
Influence of Mineral Water on Absorption of Oral Alendronate in Rats
Yuuki Akagi et al.
YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN (2011)
2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary
Alexandra Papaioannou et al.
CANADIAN MEDICAL ASSOCIATION JOURNAL (2010)
Which water for alendronate administration?
R. Pellegrini
OSTEOPOROSIS INTERNATIONAL (2009)
Risedronate dosing before breakfast compared with dosing later in the day in women with postmenopausal osteoporosis
D. L. Kendler et al.
OSTEOPOROSIS INTERNATIONAL (2009)
Medication compliance and persistence: Terminology and definitions
Joyce A. Cramer et al.
VALUE IN HEALTH (2008)
Between-meal risedronate does not alter bone turnover in nursing home residents
S Agrawal et al.
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY (2006)
Importance of calcium co-medication in bisphosphonate therapy of osteoporosis - An approach to improving correct intake and drug adherence
Johann D. Ringe et al.
DRUGS & AGING (2006)
Clinical trial of risedronate in Japanese volunteers: a study on the effects of timing of dosing on absorption
Y Ogura et al.
JOURNAL OF BONE AND MINERAL METABOLISM (2004)
The efficacy of 48-week oral ibandronate treatment in postmenopausal osteoporosis when taken 30 versus 60 minutes before breakfast
LB Tankó et al.
BONE (2003)
Pharmacokinetics of selective estrogen receptor modulators
KC Morello et al.
CLINICAL PHARMACOKINETICS (2003)
Comparison of the mineral content of tap water and bottled waters
A Azoulay et al.
JOURNAL OF GENERAL INTERNAL MEDICINE (2001)